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Title: Women with Polycystic Ovary Syndrome have intrinsic insulin resistance on euglycemic-37 
hyperinsulemic clamp. 38 
Study question: To investigate the prevalence of insulin resistance (IR) and explore intrinsic and 39 
extrinsic IR in women diagnosed with Polycystic Ovary Syndrome (PCOS) via Rotterdam criteria.  40 
Summary answer: We report novel clamp data in Rotterdam diagnosed PCOS women, using WHO 41 
criteria for IR showing that women with PCOS have a high prevalence of IR, strengthening the 42 
evidence for an aetiological role of IR in both NIH and Rotterdam diagnosed PCOS in lean and 43 
overweight women. 44 
What is known already: PCOS is a complex endocrine condition with a significant increased risk of 45 
gestational diabetes and Type 2 diabetes. 46 
Study design, size, duration: Using a cross-sectional study design, 20 overweight and 20 lean PCOS 47 
(Rotterdam criteria), 14 overweight and 19 lean BMI-matched control non-PCOS women underwent 48 
clinical measures of IR after a 3 month withdrawal of insulin sensitizers and the oral contraceptive 49 
pill. 50 
Materials, setting, methods: In an academic clinic setting, glucose infusion rate (GIR) on 51 
euglycemic hyperinsulinemic clamp was investigated as a marker of insulin sensitivity.  52 
Main results and the role of chance: PCOS women were more IR than BMI matched controls (main 53 
effect for BMI and PCOS; P<0.001). IR was present in 75% of lean PCOS, 62% of overweight 54 
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). The negative relationship between BMI and IR reflected by 57 
GIR was more marked in PCOS (y=445.1-7.7x, R
2
=0.42 [P<0.0001] than controls (y= 435.5-4.6x 58 
R
2
=0.04 [P<0.01]).  59 
Limitations, reasons for caution: The study did not use glucose tracer techniques to completely 60 
characterise the insulin resistance, as well as the lack of matching for body composition and age. 61 
Wider implications of the findings:  IR is exacerbated by increased BMI, supporting intrinsic IR in 62 
PCOS. BMI impact on IR is greater in PCOS, than in controls, irrespective of visceral fat, prioritising 63 
lifestyle intervention and the need for effective therapeutic interventions to address intrinsic IR and 64 
prevent diabetes in this high risk population.     65 
Clinical trial registration: ISRCTN84763265 66 
Keywords: Prevalence of insulin resistance; BMI; visceral fat; hyperandrogenism 67 
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Polycystic ovary syndrome (PCOS) affects 12-21% of reproductive aged women (Boyle, et al., 2012, 68 
March, et al., 2010) and has major reproductive (leading cause of anovulatory infertility) (Teede, et 69 
al., 2011), psychological (anxiety and depression) (Deeks, et al., 2010 ) and metabolic (increased type 70 
2 diabetes mellitus and cardiovascular risk factors) (Moran, et al., 2010) impacts, representing a 71 
substantial health burden (figure 1). On meta-analysis the risk of type 2 diabetes in PCOS is increased 72 
4.43 fold (OR, 95% CI 4.06 - 4.82 (Moran, et al., 2011, Moran, et al., 2010)) even after correcting for 73 
BMI. Despite PCOS prevalence and health implications, the aetiology and ideal therapies for PCOS 74 
remain unclear. Insulin resistance (IR) is a central characteristic in the majority of affected women 75 
(Teede, et al., 2007), driving both hyperandrogenism and clinical features. Underlying mechanisms of 76 
IR remain ill-defined (Teede, et al., 2011), contributing to controversy over diagnostic criteria, and a 77 
lack of optimal therapies. Therapeutic strategies in PCOS include medical therapy (metformin) 78 
(Meyer, et al., 2005), exercise (Harrison, et al., 2012, Hutchison, et al., 2011) and diet induced weight 79 
loss, which all reduce, yet do not reverse IR and fail to optimally treat PCOS. In this context, greater 80 
insight into aetiology of IR in PCOS is needed. 81 
Since the sentinel publication by Dunaif et al. (Dunaif, et al., 1989) noting increased IR in PCOS, 82 
reported prevalence of IR in PCOS has varied widely, attributable to the arbitrary and inconsistent 83 
definition of IR, the variable and often inaccurate methodologies, the heterogeneity of PCOS and the 84 
evolving diagnostic criteria. The Rotterdam criteria includes women with milder reproductive and 85 
metabolic features of PCOS and whilst theoretically IR may be less prevalent in women diagnosed via 86 
Rotterdam criteria, the prevalence of IR on clamps studies, has not been reported (Moran and Teede, 87 
2009).  88 
Whilst not useful in the clinical setting, euglycemic hyperinsulinemic clamps remain the gold 89 
standard for research based assessment of IR. Based on non-clamp data, prevalence of IR has been 90 
reported to range from 50 to 70% in women with PCOS (Carmina, et al., 1992, Legro, et al., 1998). 91 
Traditionally, this IR was attributed to obesity in PCOS (Rachon and Teede, 2010), yet it has been 92 
hypothesised that intrinsic or unique PCOS related IR is present and is compounded by separate 93 
extrinsic or BMI related IR (Diamanti-Kandarakis and Papavassiliou, 2006, Dunaif, et al., 1989, 94 
Teede, et al., 2007). The concept of intrinsic IR remains controversial in the setting of conflicting 95 
literature, with inadequate sample size and application of inaccurate methods to test IR (Dunaif, et al., 96 
1989, Mancini, et al., 2009, Rabøl, et al., 2011). Intrinsic IR has been supported by recent mechanistic 97 
PCOS studies including evidence of insulin signalling abnormalities with both unique PCOS and 98 
common BMI related abnormalities (Corbould, et al., 2005, Corbould, et al., 2006, Diamanti-99 
Kandarakis and Papavassiliou, 2006). Prior work by our group suggests that intrinsic IR in PCOS may 100 
in part be related to selectively increased visceral fat deposition in overweight women with NIH 101 
diagnosed PCOS. To progress understanding on aetiology of PCOS, IR in PCOS needs to be 102 
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examined in larger studies, using gold standard clamp methods, comprehensive analysis of visceral fat 103 
and needs to include women diagnosed by Rotterdam criteria and women across the BMI range. 104 
In this context, we hypothesise that the majority of women with PCOS diagnosed via Rotterdam 105 
criteria, will be IR and that PCOS involves both intrinsic PCOS specific IR seen in lean women, 106 
compounded by extrinsic BMI related IR in overweight women. We aimed to comprehensively 107 
examine both IR prevalence and impact of BMI across four groups: lean non-PCOS controls, lean 108 
PCOS (intrinsic IR), obese non-PCOS controls (extrinsic IR) and obese PCOS women (intrinsic + 109 
extrinsic IR), using gold standard insulin clamps. 110 
Participants and methods: 111 
Participants: 112 
Seventy three premenopausal women with and without PCOS were recruited through community 113 
advertisements. The women were categorised according to PCOS status and matched for BMI. 114 
Categorisation into BMI groups was based on the threshold BMI of 27kg.m
-2
, as an a priori decision, 115 
as this is the inflexion point in the relationship between BMI and IR (Garca-Estevez, et al., 2004) and 116 
as previously published by our group (Harrison, et al., 2012, Hutchison, et al., 2011, Hutchison, et al., 117 
2012).  Diagnosis of PCOS was undertaken by expert endocrinologists (SKH, AEJ and HJT) based on 118 
Rotterdam criteria with two of a) irregular menstrual cycles (<21 or >35 days), b) clinical (hirsutism, 119 
acne) or biochemical (elevation of at least one circulating ovarian androgen) hyperandrogenism and c)  120 
PCO on ultrasound (Group, 2004). As this work expands on a previous smaller overweight PCOS 121 
study, the exclusion criteria and screening for other causes of hyperandrogenism have been previously 122 
described (Hutchison, et al., 2011). The Southern Health Research Advisory and Ethics Committee 123 
approved the study and participants gave written informed consent. The clinical trial registration 124 
number is ISRCTN84763265. 125 
Study Design: 126 
At screening (3 months prior to testing), standard diet and lifestyle advice were delivered [Heart 127 
Foundation recommendations (www.heartfoundation.org.au)] and medications affecting end-points 128 
including insulin-sensitisers, anti-androgens and hormonal contraceptives were ceased. Data was 129 
collected in the follicular phase of the menstrual cycle where feasible.  130 
Clinical and biochemical measurements 131 
Participants anthropometric assessments including body weight, height, waist and hip circumference 132 
and Computed Axial Tomography (CT) scans for visceral fat assessments were conducted as 133 
previously reported  (Hutchison, et al., 2011).  134 
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Insulin sensitivity was assessed by the euglycemic hyperinsulinemic clamp technique as previously 135 
reported (Hutchison, et al., 2011).  Briefly, the clamp was performed 72 hours after a standardised 136 
high carbohydrate diet prior to an overnight fast. Venous fasting blood samples were collected, 137 
analysed and stored as appropriate after arterialization. Insulin (Actrapid; Novo Nordisk, Bagsvaerd, 138 
Denmark) was infused at 40mU.m
-2
 per minute for 120 minutes generating an elevated, stable insulin 139 
concentration from 10-120 min, with plasma glucose maintained at approximately 5mmol/L, using 140 
variable infusion. Glucose was assessed every five and the glucose infusion rate (GIR) was calculated 141 
during last 30 minutes of the insulin-stimulated period and expressed as glucose (mg), per body 142 
surface area (m
2
) per minute.  143 
Stored blood samples were batch analysed for serum fasting glucose, total cholesterol (TC), high-144 
density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides, 145 
insulin and testosterone and HbA1c as previously reported (Meyer, et al., 2005). Low-density 146 
lipoprotein and the homeostatic model IR assessment (HOMA) were calculated as previously 147 
described (Meyer, et al., 2005).  148 
Statistics 149 
All data are presented as mean ± SD. Results are presented for 73 participants. Two-tailed statistical 150 
analysis was performed using SPSS for Windows 20.0 software (SPSS Inc, Chicago, USA) with 151 
statistical significance was accepted when P ≤0.05. Data were assessed for normality and log 152 
transformed where appropriate and analysed using univariate ANOVA (PCOS status x body weight 153 
status) using age as a covariate. Correlations of BMI and GIR with the lipid profile parameters, and 154 
GIR with FAI were determined using the Pearson’s product moment correlation coefficient (r). 155 
Hierarchical linear regression was used to investigate the influence of visceral fat on GIR and to 156 
account for the significant age contributions to the accumulated visceral fat in all women. Split linear 157 
regressions were used to demonstrate the a priori distinction of lean and obese groups based on BMI 158 
threshold of 27 kg.m
-2
 for the exacerbation of insulin resistance in the whole group.  159 
Results 160 
We confirmed the a priori BMI categorisation into lean and overweight/obese women, based on a 161 
BMI cut-off of 27kg.m
-2
, demonstrating a stronger impact of BMI on GIR equal to or above a BMI of 162 
27kg.m
-2
 across all groups (Figure 2A). Specifically, all women with a BMI <27 kg.m
-2
 demonstrated 163 
that for every 1 BMI unit increase, GIR was 2.6 units lower (R
2
=0.005 [P=0.7]) compared to the 7.0 164 




=0.212 [P=0.007]; 165 
Figure 2A). 166 
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We analysed 34 overweight women (n=20 PCOS and n=14 controls with a BMI≥27 kg.m
-2
) and 39 167 
lean women (n=20 PCOS and n=19 Controls with a BMI<27 kg.m
-2
) with characteristics reported in 168 
Table 1. The lean women with and without PCOS, and overweight women with PCOS were well 169 
matched for age (~28 years). Overweight control women were older than other groups (P<0.001). 170 
Using age as a covariate, we noted that age did not influence outcome variables measured (P>0.05) 171 
except visceral fat (p<0.001).  172 
Women were primarily Caucasian (68%), but the cohort also included women with a European 173 
(14%), Asian/Indian (12%) and a mixed race (6%) background.   BMI, body weight, waist and hip 174 
circumference, fasting glucose, HbA1c, Triglycerides, HDL, LDL, LDL:HDL ratio, abdominal 175 
subcutaneous and visceral fat were significantly different between the combined groups of lean and 176 
obese women (main effect of BMI, P<0.05; Table 1) and were not clearly related to PCOS status. 177 
Overall, BMI and GIR correlated with triglycerides (r=0.39 [P=0.001] and r=-0.39 [P=0.001]), HDL 178 
(r=-0.61[P<0.001] and r=0.56 [P<0.001]) and the LDL/HDL ratio (r=0.53[P<0.001] and r=-0.55 179 
[P<0.001]) respectively.  180 
Testosterone and HOMA were different between lean and overweight women with PCOS (main effect 181 
of PCOS, P=0.001 and P=0.04 respectively; Table 1), and fasting insulin was different for lean and 182 
overweight women with and without PCOS (main effect PCOS, P=0.04; main effect BMI, P<0.001; 183 
Table 1).  Both BMI and PCOS were related to free androgen index (FAI; Table 1, PCOS and BMI, 184 
P<0.001, PCOS x BMI P<0.05). IR was correlated to androgen status (FAI) where r=-0.44 [P<0.001] 185 
r=-0.52 [P<0.001] for all women and women with PCOS respectively.  186 
IR is a continuous measure and is defined arbitrarily.  We defined  IR on clamp derived GIR levels as 187 
less than the 25
th
 centile of lean matched controls, (non PCOS specific World Health Organisation 188 
[WHO] criteria) (Grundy, et al., 2004). IR as determined by GIR normalised to body surface area, 189 
showed that overall PCOS women were more IR than BMI matched controls, even after correction for 190 
age (main effect for PCOS and BMI P<0.001; Figure 2B).  191 


















respectively (figure 2C). There was no significant difference in IR between lean PCOS women and 194 
overweight controls. Also, overweight women with PCOS were significantly more IR than all groups 195 
including overweight controls (figure 2C). IR was present in 75% of lean PCOS, 62% of overweight 196 
controls and 95% of overweight PCOS (figure 3A). The increased IR in PCOS is highlighted by the 197 
frequency distribution curve for GIR which is shifted to the left in PCOS (figure 3B).  198 
Lean PCOS phenotypes in this community recruited study included, 5/19 with NIH PCOS and 14/19 199 
with Rotterdam PCOS only who did not meet NIH criteria. In the overweight women, 17/20 had NIH 200 
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PCOS and 3/20 had Rotterdam criteria alone. All participants diagnosed with PCOS according to the 201 
Rotterdam criteria in both the lean and overweight groups had irregular menstrual cycles and PCO on 202 
ultrasound, with none having hyperandrogenism clinically or biochemically.   Overall 53% of PCOS 203 
women met NIH criteria. IR was present in 70% of lean Rotterdam, non NIH PCOS and 80% of lean 204 









) respectively (P<0.05). Once corrected 206 









, P<0.005) and Rotterdam only (PCO + irregular cycles) 208 




, p<0.04). 209 
There was a negative relationship between BMI and IR (GIR; Figure 2B), which is more marked in 210 
women with PCOS (PCOS R
2
=0.42 [P<0.0001] vs. controls R
2
=0.04 [P<0.01]), with every 1 unit 211 
increase in BMI associated with 7.7 unit lower GIR vs. the 4.6 units in control women (figure 2B). 212 
Visceral fat, a known major contributor to IR and assessed here via visceral fat area on CT, was 213 
negatively related to GIR, whereby after accounting for the unequal variance and age, visceral fat 214 
accounted for 39%, 31% and 39% of the GIR variance overall (adjusted r
2
=0.390; P<0.001), in 215 
controls (adjusted r
2
=0.312; P=0.002) and in PCOS (adjusted r
2
=0.392; P<0.001) women respectively.    216 
Discussion 217 
Here using gold standard clamp techniques, we confirm that PCOS women, irrespective of BMI are 218 
more IR (Dunaif, et al., 1989, Ovalle and Azziz, 2002) and report novel data that the prevalence of IR 219 
in PCOS based on the WHO definition (<25
th
 centile of GIR in healthy lean controls) is 75% in lean 220 
PCOS, 62% in overweight controls and 95% in overweight PCOS respectively in a largely Caucasian 221 
population. Overall, we show significantly higher IR in lean PCOS women versus lean controls, 222 
supporting the hypothesis that a unique intrinsic related IR exists in women with PCOS. We also 223 
confirm that extrinsic BMI related IR occurs in both control and PCOS women and demonstrate that 224 
BMI has a more potent extrinsic IR impact, than is seen in controls. On phenotypic subgroup analysis 225 
we also demonstrated that 14/19 lean Rotterdam diagnosed PCOS women who had the PCO and 226 
irregular cycle phenotype without hyperandrogenism, and did not meet NIH diagnostic criteria, still 227 
greater IR on insulin clamps than did lean controls. Finally, we report that unlike IR, lipid 228 
abnormalities appear to be primarily related to BMI and are not significantly related to PCOS status 229 
per se.   230 
IR is defined as an impaired biological response to exogenous or endogenous insulin, reflecting 231 
disturbed metabolic and mitogenic processes (Consensus Development Conference on Insulin 232 
Resistance (1998)). IR is a continuous variable measured with a range of different methodologies and 233 
defined based on controversial cut off values. Studies on IR in PCOS rarely use gold standard clamp 234 
techniques and do not conventionally include a control group to define IR based on cut offs in healthy 235 
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controls, in a given population (Grundy, et al., 2004).  Given the important role that IR play in PCOS 236 
and the high risk of type 2 diabetes, we have studied the prevalence of IR in lean and overweight 237 
PCOS women recruited from the community, using gold standard clamp methods and defined IR 238 
using WHO criteria as a GIR below the lowest quartile for the appropriate control population 239 
(Grundy, et al., 2004). We also used an age appropriate lean healthy group of women as the control 240 
group. In this context we present novel data demonstrating that overall 85% of women with PCOS  241 
were IR, with 75% of lean and 95% of obese women having WHO defined IR. Overall our data show 242 
a higher prevalence of IR in PCOS compared to other studies using clamps (Dunaif, et al., 1989, 243 
Ovalle and Azziz, 2002, Rabøl, et al., 2011), the insulin tolerance test (68-76% (Carmina, et al., 244 
1992)) or frequently sample intravenous glucose tolerance test (53% (Legro, et al., 1998)) or indeed 245 
the ethnicity independent consensus of 50-70% prevalence (Ovalle and Azziz, 2002)). These 246 
discrepancies in reported IR prevalence in PCOS across the BMI range can not only be attributed 247 
methodological differences but also the lack of a consistent definition of IR and the variable use of 248 
control populations. Given the current data, in the context of previous literature, we conclude that IR 249 
is present in the large majority of women with PCOS independent of BMI. Understanding of the high 250 
prevalence of IR in this condition arguably reduces the heterogeneity of hormonal abnormalities that 251 
contribute to metabolic and reproductive consequences of PCOS and highlights the need for greater 252 
research into the mechanistic underpinnings of IR to progress the understanding of PCOS aetiology.  253 
Conflicting results on the prevalence of IR in PCOS also stem from the evolution of the diagnosis of 254 
PCOS, from NIH to the Rotterdam criteria. Clamp data on IR in Rotterdam diagnosed PCOS women 255 
compared to controls across the BMI range has not been published to date. Rotterdam criteria remain 256 
controversial, with the additional diagnostic criteria of PCO on ultrasound resulting in more women 257 
diagnosed with PCOS and in the inclusion of women with milder reproductive and metabolic PCOS 258 
features compared to those diagnosed by NIH criteria (Moran, et al., 2011). However we have 259 
previously demonstrated that Rotterdam, non NIH PCOS cases still have metabolic abnormalities 260 
compared to controls (Moran and Teede, 2009). Here we advance knowledge in this area further by 261 
demonstrating for the first time that 70% of lean women diagnosed with PCOS on Rotterdam criteria, 262 
most of whom do not meet NIH criteria and who represent a milder reproductive PCOS phenotype, 263 
are still IR compared to BMI matched controls and have a more severe metabolic phenotype than 264 
controls. Indeed subgroup analysis of the PCO and irregular cycle phenotype without 265 
hyperandrogenism (non NIH PCOS), corrected for BMI, still had higher IR lean controls in the 266 
current study. Consistent with this finding, prior studies using less accurate measures of IR, have 267 
shown that metabolic and endocrine differences including increased IR are present in women with 268 
irregular cycles and PCO (Welt, et al., 2006), regardless of androgen status, although these features 269 
may be milder compared to women with hyperandrogenic phenotypes (Dewailly, et al., 2006). 270 
Another study using HOMA scores, did not demonstrate a difference in IR between control and PCOS 271 
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based on irregular cycles and PCO on ultrasound (Barber, et al., 2007), however insulin clamps used 272 
in the current study are a more accurate reflection of IR than HOMA scores. It appears that the more 273 
controversial Rotterdam phenotype of PCO and irregular cycles does have elevated IR when 274 
measured using accurate methods. As controversy over PCOS diagnostic criteria persist, this finding 275 
in lean women is important and suggests that even reproductively milder subgroups with PCOS do 276 
have IR and metabolic abnormalities independent of obesity.  277 
Clinical implications of this include the need to screen for metabolic complications in both NIH and 278 
Rotterdam diagnosed women, across the BMI range (Teede, et al., 2011), however when to start and 279 
how often to screen using which tests still require further research including a better understanding of 280 
the natural history of PCOS including the different phenotypes of the condition.  281 
PCOS associated (intrinsic) IR has been proposed as a contributor to PCOS aetiology for over two 282 
decades, where  significant IR was noted to occur independent of BMI (Dunaif, et al., 1989).  Others 283 
have suggested, that there is a significant IR in lean PCOS women compared to lean controls (Li and 284 
Li, 2012). However, intrinsic IR in PCOS has been contentious with a lack of consistent results, 285 
potentially related to limited quality of the data including variable use of inaccurate methods to assess 286 
and define IR in PCOS (Mancini, et al., 2009). The current study, using gold standard methodology 287 
and an internationally accepted definition of IR, demonstrates significantly higher IR in lean PCOS 288 
women versus lean controls, supporting the hypothesis that a unique intrinsic IR exists in women with 289 
PCOS. In this setting, greater understanding of the underlying mechanisms and genetic basis for 290 
intrinsic PCOS related IR is needed. Limited mechanistic IR research in PCOS, suggests aberrant 291 
peripheral insulin signalling through insulin receptor substrate 1 in PCOS, compared to controls 292 
(Corbould, et al., 2005, Corbould, et al., 2006, Diamanti-Kandarakis and Papavassiliou, 2006). Other 293 
proposed mechanisms of intrinsic IR may include reduced mitochondrial biogenesis (Skov, et al., 294 
2007) and/or function (Rabøl, et al., 2011), but the results thus to date are not supportive of this 295 
hypothesis (Hutchison, et al., 2012). Further investigation into potential mechanisms is warranted to 296 
progress understanding of PCOS aetiology and to identify potential future therapeutic targets in this 297 
common condition. Indeed current literature suggests that metformin, an insulin sensitiser, may be 298 
more effective in non-obese women with PCOS (Misso, et al., 2012), suggesting that therapies may 299 
selectively target intrinsic and extrinsic IR differentially. Likewise, the impact of lifestyle intervention 300 
may primarily target extrinsic BMI related IR in PCOS, with further research needed to clarify 301 
mechanisms of therapeutic action in PCOS.  302 
Obesity is well known to increase extrinsic IR in the general population, with the impact of BMI on 303 
IR being more marked once BMI increase beyond 27kg.m
-2
 (Garca-Estevez, et al., 2004). As we 304 
confirm here, obesity exacerbates IR in PCOS (Teede, et al., 2007) with overweight women with 305 
PCOS having higher IR  (Dunaif, et al., 1989, Hutchison, et al., 2011, Mancini, et al., 2009).  Our 306 
current data also highlights the novel finding that there is an increased impact of BMI on IR, in 307 
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women with PCOS, compared to in BMI matched controls. As visceral fat has been implicated in the 308 
aetiology of IR in obesity in PCOS (Hutchison, et al., 2011, Lord, et al., 2006).  We investigated if 309 
visceral fat accounted for the differences in IR between PCOS and controls.  Our data demonstrated 310 
that visceral fat makes similar contributions to IR in PCOS as it does in control women, indicating 311 
that visceral fat is more likely a contributor to extrinsic IR and also showing that visceral fat is not the 312 
only driver of differences in IR between PCOS and controls. The impact of BMI and visceral fat on 313 
the interaction between extrinsic and intrinsic IR in PCOS is not yet well understood and warrants 314 
further research. Overall increased BMI and increased visceral fat in PCOS reflects a significant 315 
health concern and the current data strengthens the argument for aggressive lifestyle intervention to 316 
prevent weight gain and induce weight loss to minimise associated extrinsic IR (Teede, et al., 2011). 317 
Notably, the similar degree of IR in lean PCOS and overweight control women  is consistent with the 318 
high risk of diabetes in PCOS, independent of BMI and reinforces the need for screening for glucose 319 
intolerance even in lean PCOS women (Meyer, et al., 2005, Moran, et al., 2010, Teede, et al., 2011). 320 
In contrast we did not observe a significant relationship between lipids and PCOS status, with lipids 321 
primarily related to BMI status, again highlighting the need for aggressive weight management.  322 
The strengths of the current study include a community recruited cohort of PCOS women, the 323 
extension of PCOS diagnostic criteria to include those with Rotterdam diagnosed PCOS, the use of 324 
the hyperinsulinemic euglycemic clamp methodology with pre-clamp dietary control and the inclusion 325 
of healthy controls who were matched for BMI and were not taking any medication. Limitations 326 
include not using glucose tracer techniques to completely characterise the insulin resistance, and the 327 
lack of matching for body composition and age. Also there were proportionately more women 328 
diagnosed by Rotterdam, but not NIH criteria, in the lean compared to in the overweight PCOS group. 329 
We report for the first time the prevalence of IR on clamp studies in women with Rotterdam 330 
diagnosed PCOS, where  75% of lean and 95% of overweight women with PCOS are IR, based on 331 
WHO criteria, using age appropriate lean healthy control women.  We show that the overwhelming 332 
majority of women with PCOS are IR including those who are lean and those who meet Rotterdam 333 
criteria but not NIH diagnostic criteria for PCOS, specifically those with the PCO and irregular cycle, 334 
non-hyperandrogenic PCOS phenotype. Additionally, we confirm that IR is higher in women with 335 
PCOS in the presence of an inherent, intrinsic IR that is further worsened with increasing BMI and 336 
demonstrate a more potent extrinsic IR impact of BMI in PCOS compared to controls. Given the 337 
clinical implications of insulin resistance including a high risk of type 2 diabetes, future research is 338 
needed into mechanisms of intrinsic and extrinsic IR in PCOS and into novel targeted therapies. 339 
Potentially lifestyle change may best manage extrinsic IR (Harrison, et al., 2012, Hutchison, et al., 340 
2011) and pharmacological interventions, such as metformin, may best target intrinsic PCOS related 341 
IR, however more research is needed.   342 
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Table 1.  Clinical characteristics of lean (BMI<27kg.m
-2
) and overweight (BMI>27kg.m
-2
) women 463 
with and without Polycystic Ovary Syndrome (PCOS). 464 






















      
Age (years) 27.5±6.1 27.1±4.3 34.9±4.1 29.8±5.6 0.028 <0.001 
Height (cm)
a
 165±7 166±7 164±4 164±5 0.627 0.221 
Body weight (kg)
a





 21.8±2.1 22.8±2.1 35.1±5.6 35.5±6.8 0.349 <0.001 
Waist (cm)
 a
 70.8±5.2 74.1±6.5 102.4±14.2 101.0±11.4 0.157 <0.001 
Hip (cm)
 a
 85.1±7.0 88.0±8.7 119.1±15.1 120.0±14.2 0.329 <0.001 
WHR
 a
 0.83±0.04 0.85±0.04 0.85±0.10 0.85±0.06 0.591 0.538 














23.8±8.7 25.5±9.7 119.9±60.0 172.2±82.9 0.043 <0.001 
HOMA
 a,b
 0.80±0.29 0.84±0.31 4.38±2.60 6.30±3.15 0.143 0.044  
HbA1c (%)
a
 4.7±1.2 5.0±0.1 5.4±0.3 5.4±0.4 0.439 0.002 






















234±70.9 550.3±169.1 535.2±175.4 0.635 <0.001 












 78.9±19.3 69.3±34 45.5±28.5 32.3±10.9 0.070 <0.001 
FAI 
a,c
 2.3±1.0 3.5±1.8 4.4±3.5 9.2±4.5 <0.001 <0.001 































 2.5±0.7 3.1±1.4 0.086 <0.001 
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Data are mean ±SD. BMI- Body mass index; CT-computer axial tomography; FAI- free androgen 465 
index (([testosterone]/[SHBG])*100);  HbA1c- glycosylated haemoglobin; HDL- high density 466 
lipoprotein; HOMA- Homeostatic model assessment of IR, LDL- low density lipoprotein; SHBG- 467 
steroid hormone binding globulin; WHR- waist to hip ratio.  468 
a. data analysis used age as covariate due to the significant difference between groups 469 
b. Statistical analysis reported for the log transformed data due to unequal variance. 470 
c. PCOS x BMI interaction P<0.05 471 
d. Unequal variance of data, was log transformed for statistical analysis    472 
 473 
 474 
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Figure 1: Schema of the aetiology, clinical features and health burden of polycystic ovary syndrome  477 
(reproduced from (Teede, et al., 2011) with permission).  478 
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Figure 2: The relationship 480 
between BMI and insulin 481 
resistance (IR) as determined 482 
by the glucose infusion rate 483 
(GIR) in the last 30min of the 484 
120min hyperinsulinemic- 485 
euglycemic clamp. A- 486 
Scatterplot of GIR vs. BMI 487 
where women are separated by 488 
BMI at the threshold of 27 489 
kg.m
-2
 and associated 490 
regressions lines. B- 491 
Scatterplot of GIR vs. BMI 492 
where women are separated by 493 
PCOS status, with associated 494 
regression lines. C- Mean GIR 495 
± SD data for lean control 496 
(n=19), lean PCOS (n=20), 497 
overweight/obese (ow) control 498 
(n=14) and ow PCOS (n=20) 499 
women which were 500 
significantly different from 501 
each other.  502 
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Figure 3: Insulin resistance prevalence demonstrated by A) Box and whisker plots of GIRs for lean 505 
control (n=19), lean PCOS (n=20), overweight/obese (ow) control (n=14) and ow PCOS (n=20) 506 
women with thresholds for IR in lean and ow PCOS women (World Health Organisation (WHO) 507 
defined as below the 25
th
 centiles of the Lean control group and the 1SD below the lean control mean) 508 
and B) the shift in frequency to lower GIR in women with PCOS independent of BMI.   509 
